Sandbox/v31: Difference between revisions
< Sandbox
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 23: | Line 23: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Newborn, Age <1 Week}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Newborn, Age <1 Week}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h''''' | ||
|} | |} | ||
|} | |} | ||
Line 46: | Line 46: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Newborn, Age 1—4 Weeks}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Newborn, Age 1—4 Weeks}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]]2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h''''' | ||
|} | |} | ||
|} | |} | ||
Line 69: | Line 69: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Infant & Children}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Infant & Children}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 225—300 mg/kg/day IV q6–8h''''' <BR>''OR''<BR>▸'''''[[Ceftriaxone]] 80—100 mg/kg/day IV q12–24h''''' | ||
|- | |- | ||
|} | |} | ||
Line 85: | Line 85: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Adult, Age <50 Years}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Adult, Age <50 Years}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR>▸'''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|- | |- | ||
| <SMALL><sup>†</sup> Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected.</SMALL> | | <SMALL><sup>†</sup> Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected.</SMALL> | ||
Line 103: | Line 103: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Adult, Age >50 Years}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Adult, Age >50 Years}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR>▸'''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|- | |- | ||
|} | |} | ||
Line 123: | Line 123: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Immunocompromised}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Immunocompromised}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|- | |- | ||
|} | |} | ||
Line 143: | Line 143: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Recurrent}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Recurrent}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR>▸'''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|} | |} | ||
|} | |} | ||
Line 166: | Line 166: | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Basilar Skull Fracture}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Basilar Skull Fracture}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸'''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|} | |} | ||
|} | |} | ||
Line 180: | Line 180: | ||
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;" | {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;" | ||
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Head Trauma; Post-Neurosurgery}}'' | ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Head Trauma; Post-Neurosurgery}}'' | ||
|-! style="padding: 0 5px; font-size: | |-! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8 h'''''<BR>''OR''<BR>▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR>''OR''<BR>▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|} | |} | ||
|} | |} |
Revision as of 04:36, 20 January 2014
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Sheng Shi, M.D. [3]
Empiric Therapy Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1]
Community-Acquired Meningitis ▸ Newborn, Age <1 Week
▸ Newborn, Age 1—4 Weeks
▸ Infant & Children
▸ Adult, Age <50 Years
▸ Adult, Age >50 Years
▸ Immunocompromised
▸ Recurrent
|
|
Healthcare-Associated Meningitis ▸ Basilar Skull Fracture
▸ Head Trauma; Post-Neurosurgery
|
|